#RPFs
LightNews LightNews
sukusuku.moe
they'd 100% be writing RPFs on AO3 between Uzbek politicians
November 3, 2026 at 5:16 PM
tychesgames.bsky.social
Did you know that the Teenage Mutant Ninja Turtles have their own RPG? And it is in now!

#RPFs #TTRPGs #TMNTRPG #AthensGA
TMNT RPG books
October 29, 2026 at 9:11 PM
radoh.bsky.social
Day 2 of AO3 outage.
Morale is higher than expected. Marcus has begun telling fanfictions orally around the campfire.
His hockey RPFs are a little rough around the edges, but a much needed light in this darkness.
October 30, 2026 at 12:22 PM
targetedonc.bsky.social
Missed it? This week the FDA approved talazoparib (Talzenna) + enzalutamide for HRR-mutated metastatic androgen pathway modulation–naive or –sensitive prostate cancer.

TALAPRO-3: rPFS HR of 0.48 vs placebo + enzalutamide. www.targetedonc.com/view/fda-app...
FDA Approves Talazoparib/Enzalutamide in HRR-Mutated Prostate Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
The approval expands the combination’s use to patients with androgen pathway modulation–naive or –sensitive disease based on phase 3 TALAPRO-3 findings.
www.targetedonc.com
October 31, 2026 at 1:01 AM
betweencases.bsky.social
Per FDA's Oct 26 notice, talazoparib (Talzenna) + enzalutamide is approved for mAPMN/S prostate cancer with HRR gene mutations, as detected by an FDA-authorized test. In TALAPRO-3 (599 pts), rPFS HR was 0.48; median not reached vs 45.8 months with placebo + enzalutamide.
October 28, 2026 at 3:20 PM
targetedonc.bsky.social
🚨FDA approves talazoparib + enzalutamide for HRR-mutated metastatic androgen pathway modulation–naive or –sensitive prostate cancer.

TALAPRO-3: median rPFS not reached vs 45.8 months with placebo + enzalutamide (HR, 0.48).

Read more: www.targetedonc.com/view/fda-app...
October 26, 2026 at 6:57 PM
americapharmatoday.bsky.social
FDA approved Talzenna with enzalutamide for HRR-mutated metastatic PC. rPFS not reached vs 45.8 months. OS immature.

https://americapharmatoday.com/news/fda-approves-talzenna-enzalutamide-hrr-prostate?utm_source=bluesky&utm_medium=social&utm_campaign=fda-approves-talzenna-enzalutamide-hrr-prostate
October 26, 2026 at 5:46 PM
oncoalert.bsky.social
🚨 FDA NEWS | By colleagues, for colleagues

Talazoparib + enzalutamide now approved for mAPMN/S prostate cancer with HRR gene mutations.TALAPRO-3 delivered a clear rPFS benefit (HR 0.48).
Full details & Key Facts graphic below.#OncoAlert #ProstateCancer #FDA

www.fda.gov/drugs/resour...
October 26, 2026 at 6:30 PM
merlintrader.bsky.social
$CELC Oct 23, 2026: At ESMO, Celcuity presented gedatolisib + darolutamide data in metastatic castration-resistant prostate cancer (45 pts): median rPFS 15.7 months (82.2% at 6 months) after prior abiraterone and 9.1 months after prior enzalutamide.

https://www.merlintrader.com/celc-celcuity-inc/
Celcuity $CELC: REVTORPYK Commercial Launch Confirmed
Celcuity confirms U.S. commercial availability of REVTORPYK on September 30. Uptake and revenue remain unreported; the mutant-cohort sNDA is separate.
www.merlintrader.com
October 23, 2026 at 4:28 PM
meducationai.bsky.social
This subgroup is the whole reason the FDA restricted the label to BRCA-mutated mCRPC while Europe approved it more broadly. It's a good teaching case on how an all-comers rPFS win can be carried by the biomarker-positive patients inside it.
October 14, 2026 at 5:43 PM
wonderobin.bsky.social
até porque é meio senso comum rpfs serem mantidas privadas... é pro conforto tanto de quem tá escrevendo quanto das pessoas que tão sendo escritas e tendo as vidas especuladas sobre kkkkkk aí tu faz um bglh desse e expõe pra todo mundo no IG
September 26, 2026 at 5:10 PM
wonderobin.bsky.social
nossa por isso mal posto rpf e quando posto é trancada ou em anônimo porque i do not wish to be perceived ✋ só as fics normais já me agonia se comentam fora imagina as rpfs
September 26, 2026 at 6:34 PM
celebrinie.bsky.social
de ano em ano venho aqui atualizar meus rpfs. ainda continuo doidinha por willmack só que num nível mais profundo após ter lido 70 fanfics deles
September 7, 2026 at 3:43 AM
efsa.europa.eu
🗣️ #PublicConsultation | Relative Potency Factors (RPFs)

Have your say on EFSA's draft mandate supporting guidance on the use of Relative Potency Factors (RPFs) for assessing combined exposure to multiple chemicals.

✍️ Comment by 8 October 2026.

🔗 link.europa.eu/wy7r7Y

#EUHaveYourSay
Graphic promoting an EFSA public consultation on Relative Potency Factors (RPFs) for assessing combined exposure to multiple chemicals, with a deadline of 8 October 2026.
August 31, 2026 at 8:07 AM
rattatatouille.bsky.social
Yeah but if the price of maximum engagement is seeing >100 Lestappen RPFs on AO3 then it's worth it from FOM's POV
August 23, 2026 at 3:36 PM
saintconsumed.bsky.social
no please like I knew you were a fremblem too so this was simply!!! (I'm actually more into the chopin/liszt of composer RPFs but I truly love seeing any kind of opera posting etc)
August 15, 2026 at 4:57 AM
marketwire.bsky.social
📰 #Finance
Kyntra Bio targets FG-3246 median rPFS of 10 months or greater as it plans roxadustat Phase III start in Q4 2026
seekingalpha.com
August 14, 2026 at 6:21 AM
thepcctc.bsky.social
Results of the Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE) led by the PCCTC’s Dr. Rana McKay published in JCO: ascopubs.org/doi/pdf/10.1...
Olaparib plus radium-223 significantly prolonged rPFS compared with radium-223 in men with mCRPC and BM. Despite increased hematologic toxicity, the regimen was manageable and supports further exploration of DNA damage–targeted strategies in this population.
May 15, 2026 at 11:52 AM
oncoalert.bsky.social
Join us for a discussion on rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 mirrorsmed.org/m2p-rpfs-sur...

What does it mean for clinical practice? How should it guide treatment decisions?

📺 Join Neal Shore, MD & Alicia Morgans, MD
November 7, 2025 at 1:41 PM
oncoalert.bsky.social
NOW Available on Demand: rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 library.mirrorsmed.org/index.php/ma...

What does it mean for clinical practice?
How should it guide treatment decisions?

📺 Join Neal Shore, MD @CURCMB & Alicia Morgans, MD @CaPsurvivorship @DanaFarber
October 7, 2025 at 10:44 AM
oncoalert.bsky.social
rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 library.mirrorsmed.org/index.php/ma...

What does it mean for clinical practice?
How should it guide treatment decisions?

📺 Join Neal Shore, MD
@CURCMB
& Alicia Morgans, MD
@CaPsurvivorship
@DanaFarber
September 30, 2025 at 9:30 AM
oncoalert.bsky.social
rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 buff.ly/A8SymmS

What does it mean for clinical practice?
How should it guide treatment decisions?

📺 Join Neal Shore, MD
@CURCMB
& Alicia Morgans, MD
@CaPsurvivorship
September 26, 2025 at 12:29 PM
oncoalert.bsky.social
Join us for an engaging discussion on rPFS as a surrogate for OS in patients with mHSPC
👉 library.mirrorsmed.org/index.php/ma...

Hosted by Dr. Neal Shore (START Carolinas, Myrtle Beach, SC) and Dr. Alicia Morgans (Dana-Farber Cancer Institute, Boston, MA) and brought to you by Mirrors of Medicine.
September 22, 2025 at 1:38 PM
oncoalert.bsky.social
rPFS as a surrogate for OS in mHSPC #ProstateCancer
Available now 👉 library.mirrorsmed.org/index.php/ma...

What does it mean for clinical practice?
How should it guide treatment decisions?

📺 Join Neal Shore & Alicia Morgans for an in-depth discussion and real-world case insights.
September 19, 2025 at 9:54 AM
jadehawk.bsky.social
why is the NYT publishing RPFs now
March 4, 2024 at 12:24 AM